Immunotherapeutic therapeutic drugs with anticarcinogenic.

Preparation of GA-40 is a complex of polypeptides isolated from plant material cleaner. GA-40 comprises a combination of a standardized chromatographically purified polypeptides. In medical practice, GA-40 is used as a clear colorless solution.

general characteristics:

the main physical and chemical properties: dried white powder with a specific smell;

Composition: 1 vial contains 1 mg (1000 micrograms) complex polypeptides HA-40, separated from the extract (1:40) Solomon's seal ring (Polgonatum varticillatum); Other ingredients: sodium chloride, potassium dihydrogen phosphate.

Form release. Lyophilized powder for solution for injection.

Pharmacotherapeutic group. Antineoplastic drug. Product code L01S.

Pharmacological properties

 Preclinical and clinical tests indicate that the treatment medication GA-40 with respect to tumor cells characterized by the cytotoxic activity, an immunomodulator, and relates to a drug or immunocorrectors immunoreabilitatsionnyh type.

GA-40 restores the parameters T and B cell immune systems. In particular, the normalized quantitative blood T total, active T, T-helper and T-cytotoxic, T-suppressor cells, normal killer cells (NK-cells), leukocytes, macrophages, platelets, eosinophils, basophils, stab segmented , monocytes; GA-40 restores the content of immunoglobulins in the blood reduces the erythrocyte sedimentation rate, stimulates the production of cytokines, including c-interferons and tumor necrosis factor (TNF-a).

Unlike chemo antineoplastic drugs GA-40 does not damage the normal cells of the body that determines the effect of practically harmless to any parts of the body.

GA-40privodit the norm violated different negative factors, many biochemical blood parameters: total protein, albumin, globulin, urea, creatinine, total bilirubin, free and conjugated bilirubin, glucose, and the following marker enzymes - alanine aminotransferase (ALT), aspartate -aminotransferazy (AST), g-glyutamintranspeptidazy (g-GP), alkaline phosphatase.

When treating preparatomGA-40 is observed positive dynamics of carcinoembryonic antigen (CEA), a-fetoprotein (AFP), prostate-specific antigen (PSA), and other specific tumor markers. GA-40 also has a positive effect on the blood levels of sodium, calcium, potassium and other minerals.


GA-40 is used:

In the treatment of malignant tumors.

GA-40 gives you a chance to improve the condition of patients, even in the advanced tumor processes in the treatment of the main possibilities have been exhausted traditional methods. GA-40 is characterized by a dual effect on tumor formation: direct necrotic effect on the tumor epithelial tissue of organs (ie carcinomas, but sarcomas - tumors of the connective tissue - GA-40 does not have a direct effect), and indirectly, through the activation of antitumor immunity against tumors of all types and, except for some types of leukemia. GA-40 inhibited the growth of malignant cells, promotes regression of tumors and metastasis resorption, reduces pain, improves the quality and increases the life expectancy of patients.

Application GA-40 is recommended prior to surgery as to form a primary malignant tumor metastases hidden in the body is already prevalent (70%), although their progressive development of a primary tumor is suppressed. Moreover, the primary tumor is reduced or even disables antitumor mechanisms of the immune system. GA-40 normalizes the immune system and promotes the resorption of occult metastases, thereby primary tumor is localized.

Application GA-40 is recommended as after surgery as postoperative stress, especially during the first week, usually causes a significant decrease in immunity, increasing the risk of infections and new metastases. Postoperative use of GA-40 prevents the spread of metastasis and accelerates postoperative recovery.

Application of GA-40 is recommended before the start of radiation and chemotherapy, during their implementation, as well as after their completion.

Toxic effects on the body with cancer chemotherapy and radiotherapy often cause severe complications and, therefore, forced to delay or even stop the treatment. Another problem - the initial resistance of certain tumor cells used for therapeutic drugs, as well as resistance acquired during treatment. Radiotherapy and chemotherapy also cause genetic mutations in normal cells and, as a consequence, increases the probability of a qualitatively new types of tumors.

Application of GA-40 in combination with radiotherapy and chemotherapy significantly reduces the toxic effects of these therapies, the possibility of their use and efficiency increase; the body is largely protected from the appearance of new tumors.

In the treatment of some types of leukemia.

GA-40 alone or in combination (together) with other therapies used in the treatment of acute myeloid leukemia and megacaryoblastic. When using the drug GA-40 gemapoeza marked stimulation processes, and conversion of malignant cells to normal cells.

In the treatment of benign tumors and others - mastitis, fibroma, myoma, adenoma, tsistozy and others.

In the treatment of allergic diseases - asthma and others.

In the treatment of infectious and inflammatory diseases of acute and chronic viral hepatitis (Hepatitis A, B, C) tsiroz different origin, pneumonia, bronchitis, tuberculosis, stomach ulcers and dvenadtsitiperstnoy ulcer, cholecystitis, prostatitis, trihomonioz, chlamydiosis, toxoplasmosis, cystitis, and others. )

GA-40 is used to secure the preventive treatment of genetic propensity for tumor diseases, are closely related to environmental factors. At any age in the human body every day reborn and formed hundreds of cancer cells, which are in people with a normal immune system immediately detected and eliminated. The probability of occurrence of tumors in the body, and people with weakened immune deficient especially large enough. To reduce the risk of cancer and non-specific disease, as well as to increase resistance to viral and other infectious diseases recommended twice per year in a course of treatment with GA-40, especially in persons over the age of 40-50 years.

Evaluation of therapeutic mono effects of GA-40 on 3-4 stages cancer patients.

  • The best effect (significant improvement) -12%
  • Good effect (improvement) - 33%
  • Satisfactory effect (stabilization process) -46%
  • Lack of effect - 9%
  • The negative effect (deterioration) - 0%

mode of application

GA-40 is used in the form of subcutaneous or intramuscular injection. Each vial containing the lyophilized powder is added to 5 ml of water for injection, gently shaken until complete dissolution of the powder. The dose of a single injection of 2 mg / kg body weight (0.01 ml / kg body weight). One course of treatment is 21 injections, which are held by the scheme prescribed by the doctor. Treatment continues until the complete remission of tumors and other diseases. Typically, the treatment involves at least 7 courses, with pauses between 10-14 days after which in order to prevent repeated courses are recommended one-time intervals of 2-4 months.


Application of GA-40 is contraindicated during pregnancy.

Side effects

When treating preparatomGA-40 side effects were observed. GA-40 improves the structural and functional characteristics of all the vital organs. This ensures the effectiveness and safety of not only the underlying disease, but also eliminates the side effects in monotherapy GA-40, and in kombinatsiiGA-40 with other drugs and the traditional methods.

Product form

GA-40 is produced in a lyophilized powder, or 0.02% of the finished solution for injection in vials.

Conditions and terms

The drug should be stored in a dark place at a temperature of 4 o   to 10 o C.

Shelf life: powder 12 months, as an injectable solution for 2 months.

Approved by

  • Pharmacological Committee of the Ministry of Health and Social Welfare of Georgia Department of Drugs and Pharmacology. Registration number RN № 000348, No. P 2256
  • Pharmacological Center of the Ministry of Health of Ukraine. Order number 263 of 25 May 2007. Registration number № UA / 6435/01/01.
  • Ministry of Health Series P-2010-583 KR № 7770 from 15.11.2010g.

Distributor Contact Information


Tel. +7 (495) 763-48-28
  Fax: +7 (495) 708-97-68